BR0312140A - Estratrienos 9-alfa-substituìdos como estrogênios seletivamente eficazes - Google Patents
Estratrienos 9-alfa-substituìdos como estrogênios seletivamente eficazesInfo
- Publication number
- BR0312140A BR0312140A BR0312140-2A BR0312140A BR0312140A BR 0312140 A BR0312140 A BR 0312140A BR 0312140 A BR0312140 A BR 0312140A BR 0312140 A BR0312140 A BR 0312140A
- Authority
- BR
- Brazil
- Prior art keywords
- substituted
- alpha
- estrogen
- well
- selectively effective
- Prior art date
Links
- 229940011871 estrogen Drugs 0.000 title abstract 3
- 239000000262 estrogen Substances 0.000 title abstract 3
- 150000002164 estratrienes Chemical class 0.000 title 1
- 238000002360 preparation method Methods 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010030247 Oestrogen deficiency Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000015694 estrogen receptors Human genes 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000004291 uterus Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0055—Estrane derivatives not substituted in position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10226326A DE10226326A1 (de) | 2002-06-11 | 2002-06-11 | 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene |
| PCT/EP2003/006172 WO2003104253A2 (de) | 2002-06-11 | 2003-06-11 | 9-alpha-substituierte estratriene als selektiv wirksame estrogene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0312140A true BR0312140A (pt) | 2005-04-05 |
Family
ID=29723144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0312140-2A BR0312140A (pt) | 2002-06-11 | 2003-06-11 | Estratrienos 9-alfa-substituìdos como estrogênios seletivamente eficazes |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1517914B1 (enExample) |
| JP (1) | JP4615998B2 (enExample) |
| KR (1) | KR101006612B1 (enExample) |
| CN (1) | CN1293090C (enExample) |
| AR (1) | AR040188A1 (enExample) |
| AT (1) | ATE303397T1 (enExample) |
| AU (1) | AU2003242683B9 (enExample) |
| BR (1) | BR0312140A (enExample) |
| CA (1) | CA2486495C (enExample) |
| CR (1) | CR10289A (enExample) |
| CU (1) | CU23414B7 (enExample) |
| DE (2) | DE10226326A1 (enExample) |
| DK (1) | DK1517914T3 (enExample) |
| EA (1) | EA008442B1 (enExample) |
| EC (1) | ECSP055530A (enExample) |
| ES (1) | ES2248770T3 (enExample) |
| HR (1) | HRP20050009B1 (enExample) |
| IL (1) | IL165321A (enExample) |
| MX (1) | MXPA04012491A (enExample) |
| NO (1) | NO329563B1 (enExample) |
| PE (1) | PE20040613A1 (enExample) |
| PL (1) | PL209910B1 (enExample) |
| RS (1) | RS50878B (enExample) |
| TW (1) | TWI286140B (enExample) |
| UA (1) | UA78062C2 (enExample) |
| UY (1) | UY27844A1 (enExample) |
| WO (1) | WO2003104253A2 (enExample) |
| ZA (1) | ZA200500217B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10027887A1 (de) | 2000-05-31 | 2001-12-13 | Jenapharm Gmbh | Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| EP1689410B1 (en) * | 2003-11-26 | 2008-05-21 | Bayer Schering Pharma Aktiengesellschaft | Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol |
| US7534780B2 (en) | 2004-05-21 | 2009-05-19 | Bayer Schering Pharma Aktiengesellschaft | Estradiol prodrugs |
| DE102005057224A1 (de) * | 2005-11-29 | 2007-05-31 | Bayer Schering Pharma Ag | Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| EP2252261A2 (en) * | 2008-02-13 | 2010-11-24 | Bayer Schering Pharma Aktiengesellschaft | Drug delivery system with stabilising effect |
| EP2143432A1 (en) | 2008-07-11 | 2010-01-13 | Bayer Schering Pharma AG | 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer |
| WO2010057594A1 (en) * | 2008-11-21 | 2010-05-27 | Bayer Schering Pharma Aktiengesellschaft | Drug delivery system |
| EP3185881B1 (en) | 2014-08-26 | 2022-03-09 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
| CA3109978A1 (en) * | 2018-09-07 | 2020-03-12 | Trustees Of Dartmouth College | C19 scaffolds and steroids and methods of use and manufacture thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2336432A1 (de) * | 1973-07-13 | 1975-01-30 | Schering Ag | 3.17.18-trihydroxy-1.3.5(10)-oestratriene |
| US6154158A (en) * | 1998-06-30 | 2000-11-28 | Qualcomm Incorporated | Digital-to-analog converter D.C. offset correction comparing converter input and output signals |
| DE19906159A1 (de) * | 1999-02-09 | 2000-08-10 | Schering Ag | 16-Hydroxyestratriene als selektiv wirksame Estrogene |
| EP1226155B1 (de) * | 1999-11-02 | 2007-05-02 | Bayer Schering Pharma AG | 18-nor-steroide als selektiv wirksame estrogene |
| AU5834101A (en) * | 2000-04-12 | 2001-10-23 | Schering Ag | 8ss-hydrocarbyl-substituted estratrienes for use as selective estrogens |
-
2002
- 2002-06-11 DE DE10226326A patent/DE10226326A1/de not_active Ceased
-
2003
- 2003-06-10 PE PE2003000575A patent/PE20040613A1/es not_active Application Discontinuation
- 2003-06-11 AU AU2003242683A patent/AU2003242683B9/en not_active Ceased
- 2003-06-11 UY UY27844A patent/UY27844A1/es not_active Application Discontinuation
- 2003-06-11 AT AT03757065T patent/ATE303397T1/de active
- 2003-06-11 EA EA200401544A patent/EA008442B1/ru not_active IP Right Cessation
- 2003-06-11 TW TW092115863A patent/TWI286140B/zh not_active IP Right Cessation
- 2003-06-11 ES ES03757065T patent/ES2248770T3/es not_active Expired - Lifetime
- 2003-06-11 WO PCT/EP2003/006172 patent/WO2003104253A2/de not_active Ceased
- 2003-06-11 HR HRP20050009AA patent/HRP20050009B1/hr not_active IP Right Cessation
- 2003-06-11 RS YUP-1070/04A patent/RS50878B/sr unknown
- 2003-06-11 BR BR0312140-2A patent/BR0312140A/pt not_active IP Right Cessation
- 2003-06-11 DE DE50301116T patent/DE50301116D1/de not_active Expired - Lifetime
- 2003-06-11 EP EP03757065A patent/EP1517914B1/de not_active Expired - Lifetime
- 2003-06-11 KR KR1020047020133A patent/KR101006612B1/ko not_active Expired - Fee Related
- 2003-06-11 JP JP2004511321A patent/JP4615998B2/ja not_active Expired - Fee Related
- 2003-06-11 DK DK03757065T patent/DK1517914T3/da active
- 2003-06-11 CN CNB038135027A patent/CN1293090C/zh not_active Expired - Fee Related
- 2003-06-11 PL PL373090A patent/PL209910B1/pl not_active IP Right Cessation
- 2003-06-11 MX MXPA04012491A patent/MXPA04012491A/es active IP Right Grant
- 2003-06-11 AR ARP030102079A patent/AR040188A1/es active IP Right Grant
- 2003-06-11 CA CA2486495A patent/CA2486495C/en not_active Expired - Fee Related
- 2003-11-06 UA UAA200500212A patent/UA78062C2/uk unknown
-
2004
- 2004-11-22 IL IL165321A patent/IL165321A/en not_active IP Right Cessation
- 2004-12-10 CU CU20040282A patent/CU23414B7/es not_active IP Right Cessation
-
2005
- 2005-01-10 EC EC2005005530A patent/ECSP055530A/es unknown
- 2005-01-10 NO NO20050127A patent/NO329563B1/no not_active IP Right Cessation
-
2006
- 2006-01-10 ZA ZA200500217A patent/ZA200500217B/en unknown
-
2008
- 2008-09-16 CR CR10289A patent/CR10289A/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0109983A (pt) | Estratrienos substituìdos por 8.beta-hidrocarbila como estrogênios seletivamente eficientes | |
| ES2278924T3 (es) | Composicion farmaceutica para el uso en terapia de sustitucion hormonal. | |
| ES2278925T3 (es) | Uso de compuestos estrogenicos en combinacion con compuestos progestogenicos en terapias de sustitucion hormonal. | |
| Darmani et al. | The effects of BIS-GMA and TEG-DMA on female mouse fertility | |
| AR035564A1 (es) | Moduladores selectivos de receptores de estrogenos en combinacion con estrogenos | |
| BRPI0411335A (pt) | método para preparar uma formulação de estradiol de liberação lenta, formulação farmacêutica, microesferas de estradiol e colesterol, método para efetuar contracepção e terapia de reposição hormonal simultáneas, e, kit | |
| BRPI0416700A (pt) | métodos para tratar obesidade, para alcançar perda de peso desejável, para evitar ganho de peso indesejável, e para facilitar a perda de peso em um indivìduo não sofrendo de depressão, métodos de manutenção de um peso estável e de redução do peso corporal em um indivìduo, composição farmacêutica, e, kit | |
| TNSN01130A1 (fr) | Formulations a liberation prolongee pour des secretagogues d'hormone de croissance | |
| ES2299730T3 (es) | Composicion farmaceutica que comprende derivados de estetrol para el uso en la terapia del cancer. | |
| BR0312140A (pt) | Estratrienos 9-alfa-substituìdos como estrogênios seletivamente eficazes | |
| BR0008076A (pt) | 16-hidroxiestratrienos como estrogênios de efeito seletivo | |
| Purohit et al. | Recent advances in the development of steroid sulphatase inhibitors | |
| Balfour et al. | Transdermal estradiol: a review of its pharmacological profile, and therapeutic potential in the prevention of postmenopausal osteoporosis | |
| ATE361309T1 (de) | 18-nor-steroide als selektiv wirksame estrogene | |
| EA201000097A1 (ru) | 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов | |
| US20050032758A1 (en) | Hormone replacement therapy and depression | |
| Oropeza et al. | Tofupill lacks peripheral estrogen-like actions in the rat reproductive tract | |
| YU77302A (sh) | 8beta-hidrokarbil-supstituisani estratrieni kao selektivno delotvorni estrogeni | |
| Seeger et al. | Calcium antagonistic effect of 17α-estradiol derivatives: in vitro examinations | |
| UY26967A1 (es) | Derivados 8beta-sustituidos de 11beta-pentil y 11beta-hexil-estra-1,3,5(10)-trieno.- | |
| AR033260A1 (es) | Nueva composicion hormonal y su utilizacion | |
| BRPI0406872A (pt) | Prevenção ou tratamento para desenvolvimento embrionário tardio intra-uterino ou toxemia gravìdica | |
| KR20080072087A (ko) | Ｅｒ-베타 선택적 물질의 전구약물, 그의 제조 방법 및그것을 포함하는 제약 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) |
|
| B25D | Requested change of name of applicant approved |
Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE) |
|
| B25A | Requested transfer of rights approved |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH. (DE) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |